Related Experiment Video
Updated: Feb 25, 2026

Modified Octopus Technique for Thoracoabdominal Aortic Aneurysm
Published on: August 1, 2025
Mid-Term Outcomes Following Endovascular Aneurysm Repair Using the INCRAFT Stent-Graft System
Dashuai Wang1,2,3, Yuxuan Li1,2,3, Shaojie Li4
1Center for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Abstract:
BackgroundThis study aims to investigate the durability and outcomes of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) using the low-profile INCRAFT Stent-Graft System.MethodsBaseline characteristics, procedural data, and clinical outcomes were retrospectively collected from patients diagnosed with infrarenal AAAs, who underwent elective EVAR using the INCRAFT device from August 2017 to March 2023 at our institute.ResultsThirty-two patients with a mean age of 72.72 ± 7.18 years were included in the study, and 84.4% of the patients had hostile iliac accesses. The immediate technical success rate of INCRAFT device implantation was 100%, and clinical success was obtained in all patients post-procedure. The intraprocedural endoleak (EL) rate was 15.6%, with three cases of type 1a EL and two cases of type 1b EL (resolved after percutaneous transluminal angioplasty). Reintervention was required in 5 patients, four of whom underwent successful transarterial embolisation for type 2 EL; one of the patient underwent proximal extension for type 1a EL. During a median post-procedural follow-up of 32 months, there were no aneurysm-related deaths, stent-graft migration, or aneurysm-related ruptures. Freedom from all-cause mortality was 93.8%, and freedom from secondary intervention was 84.4% at 3 years.ConclusionsIn this real-world study setting, the midterm outcomes of the INCRAFT Stent-Graft System showed no aneurysm-related deaths. The use of this low-profile device for infrarenal AAAs is associated with sustained success and relatively low rates of reintervention during follow-up, which represents a safe and effective option for endovascular treatment in patients with hostile iliac accesses.
